Clinical Study

Inflammatory Markers and Obstructive Sleep Apnea in Obese Children: The NANOS Study

Alex Gileles-Hillel, María Luz Alonso-Álvarez, Leila Kheirandish-Gozal, Eduard Peris, José Aurelio Cordero-Guevara, Joaquin Terán-Santos, Mónica Gonzalez Martinez, María José Jurado-Luque, Jaime Corral-Peñafiel, Joaquin Duran-Cantolla, and David Gozal

1 Section of Sleep Medicine, Department of Pediatrics, Comer Children’s Hospital, Pritzker School of Medicine, Biological Sciences Division, The University of Chicago, 5721 S. Maryland Avenue, Chicago, IL 60637, USA
2 Sleep Unit, Instituto Carlos III.CIBERES, Spain
3 CIBER of Respiratory Diseases, Instituto Carlos III.CIBERES, Spain
4 Hospital Universitario de Burgos (HUBU), Burgos, Spain
5 Hospital Universitario Valdecilla, Santander, Spain
6 Hospital Val d’Hebron, Barcelona, Spain
7 Hospital San Pedro de Alcántara, Caceres, Spain
8 Servicio de Investigación, Hospital Universitario Araba (BioAraba), Universidad del País Vasco (UPV/EHU), Vitoria, Spain

Correspondence should be addressed to David Gozal; dgozal@uchicago.edu

Received 13 March 2014; Revised 17 April 2014; Accepted 1 May 2014; Published 1 June 2014

Academic Editor: Jean Louis Pepin

Copyright © 2014 Alex Gileles-Hillel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Obesity and obstructive sleep apnea syndrome (OSA) are common coexisting conditions associated with a chronic low-grade inflammatory state underlying some of the cognitive, metabolic, and cardiovascular morbidities. Aim. To examine the levels of inflammatory markers in obese community-dwelling children with OSA, as compared to no-OSA, and their association with clinical and polysomnographic (PSG) variables. Methods. In this cross-sectional, prospective multicenter study, healthy obese Spanish children (ages 4–15 years) were randomly selected and underwent nocturnal PSG followed by a morning fasting blood draw. Plasma samples were assayed for multiple inflammatory markers. Results. 204 children were enrolled in the study; 75 had OSA, defined by an obstructive respiratory disturbance index (RDI) of 3 events/hour total sleep time (TST). BMI, gender, and age were similar in OSA and no-OSA children. Monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) levels were significantly higher in OSA children, with interleukin-6 concentrations being higher in moderate-severe OSA (i.e., AHI > 5/hr TST; P < 0.01), while MCP-1 levels were associated with more prolonged nocturnal hypercapnia (P < 0.001). Conclusion. IL-6, MCP-1, and PAI-1 are altered in the context of OSA among community-based obese children further reinforcing the proinflammatory effects of sleep disorders such as OSA. This trial is registered with ClinicalTrials.gov NCT01322763.

1. Introduction

Sleep-disordered-breathing (SDB) is a group of common disorders characterized by habitual snoring along with varying degrees of gas exchange alterations and sleep fragmentation [1]. Obstructive sleep apnea (OSA) is the most prevalent of those disorders affecting 1–4% of children with a peak incidence around 2–8 years [2]. In recent years, it has become apparent that the frequency of OSA is markedly increased by the concurrent presence of obesity [3] and the coexistence of these 2 conditions has been linked to a higher risk for development of end-organ morbidities, including neurocognitive and behavioral impairments and cardiovascular and metabolic dysfunction [4–8]. In addition to increased
oxidative stress, activation and propagation of inflammatory pathways in the context of immune dysregulation have been implicated in the deleterious consequences of OSA [9, 10], with the cumulative evidence strongly supporting the concept that pediatric OSA is a chronic, low grade inflammatory condition [11–16]. In this context, it is now recognized that OSA causes, albeit not always, systemic elevation in the levels of inflammatory mediators, such as CRP, TNFα, IL-6, and INF-γ [17–23], and the concomitant reduction of anti-inflammatory substances, such as IL-10, thereby tilting the balance toward a heightened proinflammatory state [24].

Similarly, obesity has long been recognized as an indolent and persistent inflammatory condition in which the sustained activity of such processes promotes the occurrence of insulin resistance and vascular dysfunction [25–29]. OSA and obesity frequently coexist in children and have been assumed to interact and promote each other [30–32]. However, the potential contributions of OSA to the proinflammatory profile of obese children have not been critically delineated, particularly considering the incongruent inflammatory phenotypes that have been previously reported in obese children [33]. Thus, we hypothesized that community-recruited obese children with OSA would display significant differences in their plasma levels of specific biomarkers, including inflammatory markers. The aim of the present study was to assess and better delineate the potential effects of perturbed sleep, such as occurs in OSA, on a panel of inflammatory markers. The morning after the PSG, blood was drawn in fasting conditions.

2.1. Overnight Polysomnography. PSG tests were conducted in a sleep laboratory under standardized conditions. The studies were scored, after removal of movement and technical artifacts, according to the standard criteria defined by the American Academy of Sleep Medicine (AASM) [36]. Briefly, obstructive sleep apnea was defined as cessation of airflow with continued chest wall and abdominal movements for the duration of at least two breaths. Hypopnea was defined as a decrease in nasal flow greater than 50%, corresponding to at least 4% decrease in the oxygen saturation (SpO2) as measured by pulse oximetry and/or terminated by a 3-second EEG arousal. The obstructive apnea-hypopnea index (AHI) was defined as the number of apneas and hypopneas per hour of total sleep time (TST). The obstructive respiratory disturbance index (RDI) was calculated from the number of respiratory-effort-related arousals and the number of apneas and hypopneas per hour of TST. Children with OSA were defined as those having RDI ≥ 3/hr of TST in accordance with the clinical practice guidelines in Spain [37]. In addition, nadir and mean SpO2, as well total sleep time during which SpO2 is below 90% or end-tidal CO2 > 50 mmHg occurred, were recorded. Oxygen desaturation index (ODI) was defined as the number of desaturation events ≥ 4% per hour of TST. Of note, in our subanalyses we defined moderate-to-severe OSA, as the presence of obstructive AHI > 5/hrTST.

2.2. Inflammatory Mediator Assays. Plasma was separated from the whole blood morning samples drawn from each child and stored in −80°C until assay. Commercially available ELISA kits specific for each cytokine were used to measure levels of IL-6, IL-18, MCP-1, adiponectin, MMP-9, apelin C, leptin (all individual kits from RayBiotech, Inc., Norcross, GA, USA), adiperin (Peninsula laboratories LLC, San Carlos, CA, USA), osteocrin (MyBioSource, San Diego, CA, USA), and PAI-1 (Assaypro LLC, St. Charles, MO, USA). Assays were performed according to manufacturers’ recommendations.

2.3. Statistical Analysis. Descriptive data for continuous variables are presented as means ± standard deviation (SD) and for categorical variables as percentages or ratios. Analyses for comparisons between clinical and laboratory values among OSA and no-OSA groups were performed using Student’s t-tests for continuous and χ² tests for categorical variables followed by Fisher exact tests. Group comparisons were conducted using one-way ANOVA followed by Bonferroni correction for multiple comparisons. Pearson’s correlation was used to compare between the marker levels and clinical parameters. Multivariate linear regression analysis was applied to assess relationships of significantly different markers between the two groups of children. Statistical significance was assumed at two-tailed P < 0.05. Statistical analyses were performed using SPSS software (version 21.0; SPSS Inc., Chicago, IL).

2. Subjects and Methods

204 obese children (ages 4–15 years) were recruited from the community in a multicenter prospective study in Spain—the NANOS study. A detailed account of the study design is described elsewhere [34]. Briefly, obese children were prospectively enrolled through primary care centers across Spain during 2007–2010 and were randomly selected to participate in the study. The study was approved by a human subject committee in each of the participating centers and is in accordance with the STROBE statement. The study was registered at ClinicalTrials.gov under NCT01322763. Informed consent was obtained from each subject or legal guardian, and assent was obtained from children above 12 years old. Data was coded so each investigator in the research network was blinded to subjects’ personal information and thus ensuring confidentiality. Samples and data from subjects included in this study were provided by the Basque Biobank for research OEHUN (http://www.biobancovasco.org/) and were processed following standard operating procedures with appropriate approvals from the Ethical and Scientific Committees.

The general medical and sleep histories were obtained from all participating children and the parents filled a validated Spanish version of the Pediatric Sleep Questionnaire (PSQ) [35]. Every child then underwent a thorough medical examination followed by an overnight sleep study (PSG).
**Table 1:** Antropometric measures in OSA and no-OSA obese children.

|                      | Total (𝑛=204) | No-OSA (𝑛=129) | OSA (𝑛=75) | 𝑃 value |
|----------------------|---------------|----------------|------------|---------|
| **Age (years)**      | 10.8 ± 2.6    | 11 ± 2.4       | 10.4 ± 2.8 | 0.1     |
| **Gender (male/female)** | 111/93      | 72/57          | 39/36      | 0.6     |
| **Height (m)**       | 1.5 ± 0.16    | 1.5 ± 0.16     | 1.46 ± 0.17| 0.1     |
| **Weight (Kg)**      | 64.3 ± 21.1   | 65.2 ± 20.6    | 62.7 ± 22.1| 0.4     |
| **BMI**              | 27.9 ± 4.3    | 27.9 ± 4.1     | 28 ± 4.6   | 0.8     |
| **BMI%**             | 96.8 ± 0.6    | 96.7 ± 0.6     | 96.8 ± 0.4 | 0.4     |
| **Neck circumference (cm)** | 34.1 ± 3.8 | 33.9 ± 3.8     | 34.3 ± 3.7 | 0.5     |
| **Waist circumference/hip circumference** | 0.9 ± 0.07 | 0.9 ± 0.07     | 0.9 ± 0.07 | 0.6     |

*Data presented as mean ± SD.*

**Table 2:** Polysomnographic characteristics in OSA and no-OSA obese children.

|                      | Total (𝑛=204) | No-OSA (𝑛=129) | OSA (𝑛=75) | 𝑃 value |
|----------------------|---------------|----------------|------------|---------|
| **AHI (/hrTST)**     | 3.6 ± 9.5     | 0.6 ± 0.6      | 9 ± 14.2   | < 0.001†|
| **Time in Bed (min)** | 479.2 ± 45.8  | 482.8 ± 47     | 473.1 ± 43.4 | 0.1     |
| **Total sleep time (min)** | 379.6 ± 70.2 | 384.1 ± 70.7   | 372 ± 69.4 | 0.2     |
| **Sleep Efficiency%** | 78.9 ± 12.8   | 78.9 ± 12.3    | 78.9 ± 13.9| 0.9     |
| **Number of arousals** | 67.3 ± 62.5   | 48.2 ± 32.9    | 99.4 ± 84.1| < 0.001†|
| **Arousal index (/hrTST)** | 11.2 ± 11.2 | 7.9 ± 6.1      | 17 ± 15.1  | < 0.001†|
| **Respiratory disturbance index (/hrTST)** | 6 ± 10.6 | 1.4 ± 1        | 14 ± 14.5  | < 0.001†|
| **Obstructive RDI (/hrTST)** | 5.5 ± 10.3 | 1.0 ± 0.9      | 13.3 ± 13.9| < 0.001†|
| **Central RDI (/hrTST)** | 0.3 ± 1      | 0.2 ± 0.4      | 0.6 ± 1.7  | 0.01†   |
| **Baseline SpO2 (%)** | 98.1 ± 1.4    | 98.3 ± 1.3     | 98 ± 1.7   | 0.2     |
| **Mean SpO2 (%)**     | 96.4 ± 1.5    | 96.7 ± 1.2     | 96.1 ± 1.9 | 0.008§  |
| **Nadir SpO2 (%)**    | 90.5 ± 5.2    | 91.4 ± 3.5     | 89.1 ± 7   | 0.003§  |
| **Time SpO2 < 90%**   | 1.1 ± 7.2     | 0.5 ± 3.3      | 2.3 ± 11.4 | 0.1     |
| **Oxygen desaturation index (/hrTST)** | 2.3 ± 9 | 0.7 ± 1.2      | 5.1 ± 14.2 | 0.001†  |
| **Peak end-tidal CO2 (mmHg)** | 46.2 ± 6.9 | 46.1 ± 6.1     | 46.2 ± 8.3 | 0.9     |
| **Total Sleep time with end-tidal CO2 > 50 mmHg (hours)** | 3.6 ± 11.8 | 1.6 ± 5.6      | 7.1 ± 17.7 | 0.003§ |

†Statistically significant difference.

### 3. Results

#### 3.1. Demographic Data.
204 obese children from the community (ages 4–15 years) were recruited from the NANOS study, 111 boys and 93 girls, all fulfilling obesity criteria, that is, BMI above the 95% for age and gender [38]. The prevalence of OSA in this group of obese children was 36.7%. The 2 groups of children, those with (OSA) and without OSA (no-OSA), had similar demographic and anthropometric characteristics (Table 1).

#### 3.2. Sleep Studies.
PSG findings are summarized in Table 2 for the 2 groups. As would be anticipated from the OSA and no-OSA category allocation, most of the PSG variables differed, and most particularly for respiratory parameters and the number of arousals from sleep (Table 2). In contrast, there were no significant differences in either the total duration of sleep and total time in bed (Table 2). These findings support the idea that disruption of sleep architecture, that is, sleep fragmentation, rather than sleep deprivation, is the salient sleep perturbation among children with OSA [4].

#### 3.3. Plasma Inflammatory Mediators in Obese Children: OSA versus No-OSA.
Among the inflammatory markers included in the present study, 2 markers were significantly higher in the OSA group, namely, PAI-1 (Table 3; 𝑃 = 0.01) and MCP-1 (Table 3; 𝑃 = 0.03). In a subset of children with more severe OSA (i.e., AHI > 5/hrTST), significantly higher levels of IL-6 emerged (𝑃 = 0.009; Table 3). In addition, MCP-1 levels of ≥30 pg/mL and PAI-1 of ≥3.3 ng/mL conferred a modestly higher risk of OSA (OR = 2, CI<sub>95%</sub> = 1.1–3.6, 𝑃 = 0.02; OR = 1.8, CI<sub>95%</sub> = 1.3–3.2, 𝑃 = 0.04, resp.).

To further examine the global contribution of inflammatory markers to the overall inflammatory state of each child, we constructed a cumulative "inflammatory score" (IS), whereby each marker was standardized using z-score transformation. The IS was then calculated by summarizing all the individual z scores. Please note that the z scores for adiponectin and adiponin were calculated and multiplied by −1, since their plasma levels have been reported to decrease in states of increased inflammation and obesity. The IS was significantly higher in the OSA as compared to no-OSA groups (Table 3; 𝑃 = 0.04).
No differences in inflammatory marker levels emerged between boys and girls in the full cohort, except for higher plasma levels of leptin among girls (17.1 versus 21.3 ng/mL, \( P < 0.001 \)). Of note, girls had slightly lower baseline and mean SpO\(_2\) levels during the PSG (mean difference \( \sim 0.5\% \), \( P = 0.01 \)) and a trend toward lower BMI\(\%\) (96.8 versus 96.7\%), \( P = 0.007 \). In a linear regression model that included all of the above variables that had significant correlations with IS, BMI, and TCO\(_2\) > 50 independently predicted higher IS (\( \beta = 0.296, P = 0.001; \beta = 0.360, P < 0.001 \)).

Next, we examined whether any of the specific markers was potentially useful in predicting clinically relevant components of sleep-disordered breathing among the 75 children with OSA, that is, sleep fragmentation, intermittent hypoxemia, and hypercapnia. Pearson correlation coefficients (PCC) are presented and only the results that remained statistically significant after age adjustment are presented below, given the considerable changes in marker levels as a function of age (Table 4).

### 3.4. Correlation Analyses

First, we examined whether the various biomarkers were associated with both PSG-derived measures and anthropometric measurements in the full cohort (\( n = 204 \); Table 3). Higher MCP-1 levels correlated with ODI (\( r = -0.171; P = 0.02 \)), with TCO\(_2\) > 50 (\( r = 0.352; P < 0.001 \)) and was inversely associated with TST (\( r = -0.172, P = 0.007 \)) and sleep efficiency (\( r = -0.142, P = 0.026 \)). In a linear regression model that included all of the above variables that had significant correlations with IS, BMI, and TCO\(_2\) > 50 independently predicted higher IS (\( \beta = 0.296, P = 0.001; \beta = 0.360, P < 0.001 \)).

Additionally, IS had a strong positive correlation with BMI (\( r = 0.241, P < 0.001 \)), neck circumference (\( r = 0.226, P < 0.001 \)), age (\( r = 0.154, P = 0.01 \)), and TCO\(_2\) > 50 (\( r = 0.294, P < 0.001 \)) and was inversely associated with TST (\( r = -0.172, P = 0.007 \)) and sleep efficiency (\( r = -0.142, P = 0.026 \)). In a linear regression model that included all of the above variables that had significant correlations with IS, BMI, and TCO\(_2\) > 50 independently predicted higher IS (\( \beta = 0.296, P = 0.001; \beta = 0.360, P < 0.001 \)).

### Table 3: Inflammatory markers in OSA and non-OSA obese children.

|                  | Total (\( n = 204 \)) | No-OSA (\( n = 129 \)) | OSA (\( n = 75 \)) | \( P \) value |
|------------------|------------------------|------------------------|-------------------|--------------|
| IL-6 (pg/mL)     | 7.5 ± 3.8 [7–8.1]      | 7.3 ± 3.2 [6.7–7.8]   | 8 ± 4.8 [6.8–9.1] | 0.2          |
| IL-18 (pg/mL)    | 170.2 ± 96.8 [156.9–183.6] | 163.2 ± 80.8 [149.1–177.2] | 182.4 ± 119.2 [155.1–209.9] | 0.17         |
| PAI-1 (ng/mL)    | 3.3 ± 1.2 [3–3.5]      | 3.2 ± 1.2 [2.9–3.4]   | 3.6 ± 1.3 [3.3–3.9] | 0.01†        |
| MCP-1 (pg/mL)    | 35.1 ± 16.9 [32.8–37.5] | 33.2 ± 15.2 [30.6–35.9] | 38.4 ± 19.1 [34–42.8] | 0.03†        |
| Adiponectin (μg/mL) | 28.1 ± 13.3 [26.2–29.9] | 26.8 ± 12.1 [24.6–28.9] | 30.3 ± 14.9 [26.8–33.7] | 0.07         |
| MMP-9 (μg/mL)    | 0.9 ± 0.6 [0.85–1]     | 0.9 ± 0.5 [0.8–0.97]  | 1 ± 0.8 [0.85–1.2]  | 0.1          |
| Osteocrin (ng/mL) | 8.5 ± 12.6 [6.7–10.2]  | 7.8 ± 7.2 [6.5–9.1]   | 9.7 ± 18.5 [5.5–14] | 0.3          |
| Leptin (ng/mL)   | 19.1 ± 8.1 [17.9–20.2] | 18.5 ± 8.2 [17.1–19.9] | 20 ± 8 [18.1–21.8] | 0.2          |
| IS               | 0 ± 4.3 [−0.49–4.9]    | −0.5 ± 3.4 [−1.1–0.13] | 0.8 ± 5.4 [−0.43–2.1] | 0.04†        |

*Data presented as mean ± SD (CI95%). †Statistically significant difference; IS: inflammatory cumulative score.
C exhibited a strong positive correlation with TCO₂ > 50 (r = 0.511; P < 0.001).

In a multivariate analysis that included all the marker levels in the OSA group aiming at correcting for intermarker correlations, age-adjusted MCP-1 levels remained the only inflammatory mediator that independently predicted TCO₂ > 50 (β = 0.322, P = 0.03). Furthermore, age-adjusted leptin levels in the OSA group independently predicted lower TST (β = −0.252, P = 0.04). Inflammatory score (IS) was correlated in the OSA group with higher TCO₂ > 50 (r = 0.359, P = 0.002) and had borderline association with neck circumference (r = 0.213, P = 0.049). Only higher TCO₂ > 50 independently predicted higher IS (β = 0.356, P = 0.003) in the OSA group in a model that included age, BMI, and neck circumference.

### 4. Discussion

Current findings provide incremental evidence that the presence of OSA operates as an independent contributor to the increased systemic inflammation that occurs in obese children. Our data indicate that the levels of two blood markers, namely, PAI-1 and MCP-1, were increased among obese children with OSA, such that plasma concentrations of MCP-1 > 30 pg/mL and PAI-1 > 3.3 ng/mL provide reliable prediction on the presence of OSA. In addition, in a subset of obese children with moderate-to-severe OSA, IL-6 levels were also significantly higher. Furthermore, the overall inflammatory status, as inferred from the inflammatory score (IS), an arbitrary additive summation of the relative levels of all the current markers assayed in this study, was significantly increased in the OSA group, indicating heightened overall inflammatory load in OSA. Interestingly, IS also exhibited significant associations with BMI and total sleep time and efficiency as well as with the duration of hypercapnia.

Before discussing the potential implications of our findings, we will initially focus on those 3 inflammatory mediators that were markedly elevated in the OSA group, MCP-1, PAI-1, and IL-6. Monocyte chemoattractant protein 1 (MCP-1) is a central member of the C-C chemokine superfamily responsible for attracting mononuclear cells to inflammatory sites [39]. MCP-1 increases with obesity, plays a role in recruiting macrophages into adipose tissue in adult obese patients [40–42], and is associated with insulin resistance and with type 2 diabetes [43]. This cytokine, which is also highly expressed in the inflamed vasculature, is a potent attractor of lipid-activated monocytes involved in the inflammatory signaling cascade related to vascular dysfunction, atherosclerosis, and cardiac events [44, 45]. In children, there is also evidence that MCP-1 increases with obesity [46, 47]. In the context of OSA, MCP-1 elevations have been reported in adult patients, and treatment with CPAP reduced MCP-1 levels [48, 49]. The negative association reported herein between ODI and MCP-1 levels was unexpected considering that MCP-1 gene expression increases in response to hypoxia and appears to correlate with the degree of hypoxemia in adult patients with OSA [50]. PAI-1 is an inhibitor of tissue plasminogen activator and primarily functions as a suppressor of plasma fibrinolysis. PAI-1 increases in plasma are believed to play a role in the pathophysiology of endothelial dysfunction and atherothrombosis [51]. PAI-1 has been recently shown to have a strong correlation with known cardiometabolic risk factors in adults and is proposed as a biomarker for metabolic syndrome [52]. Similarly, higher PAI-1 levels have been associated with higher risk for microvascular complications in children, as well as with poorer diabetes control and hyperlipidemia in patients with type 1 diabetes [53]. In the context of OSA, higher levels of PAI-1 have been previously described in adults [54, 55]. Here, we show for the first time that obese children with OSA have higher plasma levels of PAI-1, supporting the notion that such alterations may reflect an underlying risk for vascular dysfunction, even if measures of endothelial function were not specifically acquired. Indeed, early development of endothelial dysfunction in pediatric OSA has been the subject to recent and intense research efforts which have led to the demonstration that the microvascular bed is a target of OSA [7, 8, 56–58]. Interleukin-6 is a ubiquitously expressed proinflammatory cytokine and well-established risk factor for adverse cardiovascular outcomes [59]. IL-6 signaling pathways are involved in the liver synthesis of C-reactive protein (CRP), and CRP is elevated in children with sleep-disordered breathing, whereby both IL-6 and CRP levels correlate with degree of hypoxemia and sleep disruption, independently of the degree of obesity [60]. Elevated IL-6 levels have been now repeatedly described in both adults and children with OSA [61, 62], and genetic variations in the IL-6 gene are associated with pediatric OSA and may account for the increased CRP levels seen in those children [23]. Thus, the increased IL-6 levels in the moderate-severe group of OSA children may provide a useful indicator for the presence of a more severe clinical phenotype. However, we cannot exclude the possibility that the different genomic background in this population may account for a decreased likelihood of finding elevated IL-6 plasma concentrations as recently reported in a comparison of US and Greek children [23].

Our study is the first to examine a large pediatric cohort of obese children from the community (i.e., not clinically
referred children) and evaluated these children in an unbi-
ased fashion for the presence of sleep-disordered breathing.
These were therefore a priori healthy children without any
preexisting conditions except for the presence of obesity. All
previous studies in which the proinflammatory effects and
metabolic consequences of obesity were explored consisted of
symptomatic, clinically-referred obese children being evalu-
ated for management of their obesity and with a high prev-
alence of OSA, precluding systematic determination of the
relative contribution of OSA to the inflammatory profile of
obesity [3, 18, 19, 63, 64]. As reported above, the increase in
individual inflammatory markers and in the overall IS among
the OSA group was independent of the degree of obesity. Fur-
thermore, all 3 markers altered by OSA are ascribed patho-
physiological roles in cardiovascular dysfunction, thereby
suggesting that OSA in obese children might predispose them
to a more severe cardiovascular phenotype and to earlier de-
velopment of cardiovascular morbidities. Based on our pre-
vious study showing that obese children with OSA have a
significantly higher proportion of abnormal endothelial func-
tion [7], more aggressive diagnostic and intervention mea-
sures appear to be warranted by the concurrent presence
of obesity and symptoms of OSA. Conversely, children with
milder forms of sleep-disordered breathing, that is, RDI < 3/
hrTST, had lower systemic inflammatory markers, potentially
justifying the expectant approach strategy as recently recom-
mended [65].

An interesting association emerged between increased
BMI and leptin levels and decreased total sleep time during
the overnight PSG. Such association concurs with epidemi-
ological studies showing that sleep loss is associated with
increased obesity, increased appetite, and elevated leptin lev-
els in adults [66], and with similar recent findings in children
[67]. Of note, reduced duration is not a primary feature of
OSA, as confirmed by the similar total sleep time in OSA and
no-OSA children in the present study.

The strong association between prolonged hypercapnia
and increased inflammation deserves comment. Obesity-
hypoventilation syndrome (OHS) is a relatively infrequent
condition in children that is characterized by airway obstruc-
tion and CO₂ retention [68]. OHS is relatively underdiag-
nosed, and in adults it has been associated with impaired daily
functioning and increased risk for diabetes and cardiovascu-
lar morbidity (including systemic and pulmonary hyperten-
sion, ischemic heart disease, and right-heart failure), as well
as with higher risk of hospitalization and death [69–72]. The
occurrence of alveolar hypoventilation during sleep is much
more common in obese children with OSA when compared
with children with OSA who are not obese [73, 74], and the
present study illustrates for the first time the possibility that
children with increased CO₂ retention may represent a high
risk group.

In summary, systemic inflammation is more pronounced
in obese children with OSA, further buttressing the contribu-
tions of perturbed sleep and gas exchange abnormalities to
the inflammatory cascade. Further studies are needed to in-
vestigate the role of PAI-1 as a marker of endothelial dysfunc-
tion and the role of hypercapnia on increased inflammation
and end-organ injury in obese and nonobese children with
OSA.

Conflict of Interests
The authors have no conflict of interests to declare.

Acknowledgments

Leila Kheirandish-Gozal and David Gozal are supported by a
Grant HL-65270 from the National Institutes of Health. The
NANOS study was supported by the Spanish Respiratory
Society (SEPAR) and Mutua Madrileña. The authors thank
the subjects and their parents for their participation and
the Basque Biobank For Research-ŒEHUN for their collab-
oration. The authors would like to thank the members of
the Spanish Sleep Network: Estrella Ordax Carbajo, M.D.
(Hospital Universitario de Burgos); Ana Isabel Navazo-
Eguí, M.D. (Hospital Universitario de Burgos); Marian
Martinez Martinez, M.D. (Hospital Universitario Valdecilla,
Santander); Odile Romero Santo-Tomas, MD (Hospital Val
D’Hebron); Fernando Masa-Jimenez, M.D. (Hospital San
Pedro de Alcantara, Caceres); Cristina Martinez Null (Hospit-
al Universitario Araba, Vitoria); Antonia Barcelo-Bennassar,
Ph.D. (Hospital Son Dureta, Palma de Mallorca).

References

[1] L. Kheirandish-Gozal and D. Gozal, Sleep Disordered Breathing in Children: A Comprehensive Clinical Guide to Evaluation and Treatment, Springer, New York, NY, USA, 2012.
[2] H. L. Tan, D. Gozal, and L. Kheirandish-Gozal, “Obstructive sleep apnea in children: a critical update,” Nature and Science of Sleep, vol. 5, pp. 109–123, 2013.
[3] R. Tauman and D. Gozal, “Obesity and obstructive sleep apnea in children,” Paediatric Respiratory Reviews, vol. 7, no. 4, pp. 247–259, 2006.
[4] O. S. Capdevila, L. Kheirandish-Gozal, E. Dayyat, and D. Gozal, “Pediatric obstructive sleep apnea: complications, management, and long-term outcomes,” Proceedings of the American Thoracic Society, vol. 5, no. 2, pp. 274–282, 2008.
[5] D. Gozal, O. S. Capdevila, and L. Kheirandish-Gozal, “Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 10, pp. 1142–1149, 2008.
[6] K. Spruyt and D. Gozal, “A mediation model linking body weight, cognition, and sleep-disordered breathing,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 2, pp. 199–205, 2012.
[7] R. Bhattacharjee, J. Kim, W. H. Alotaibi, L. Kheirandish-Gozal, O. S. Capdevila, and D. Gozal, “Endothelial dysfunction in children without hypertension: potential contributions of obesity and obstructive sleep apnea,” Chest, vol. 141, no. 3, pp. 682–691, 2012.
[8] D. Gozal, L. Kheirandish-Gozal, R. Bhattacharjee, H. Molero-Ramirez, H.-L. Tan, and H. P. R. Bandla, “Circulating adiponectin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function,” The Journal of Pediatrics, vol. 163, no. 4, pp. 1122–1126, 2013.
Mediators of Inflammation

[9] A. D. Goldbart, J. Krishna, R. C. Li, L. D. Serpero, and D. Gozal, “Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome,” *Chest*, vol. 130, no. 1, pp. 143–148, 2006.

[10] D. Gozal, “Sleep, sleep disorders and inflammation in children,” *Sleep Medicine*, vol. 10, supplement 1, pp. S12–S16, 2009.

[11] D. Gozal, V. M. Crabtree, O. S. Capdevila, L. A. Witcher, and L. Kheirandish-Gozal, “C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children,” *American Journal of Respiratory and Critical Care Medicine*, vol. 176, no. 2, pp. 188–193, 2007.

[12] D. Nair, E. A. Dayyat, S. X. Zhang, Y. Wang, and D. Gozal, “Intermittent hypoxia-induced cognitive deficits are mediated by NADPH oxidase activity in a murine model of sleep apnea,” *PloS ONE*, vol. 6, no. 5, Article ID e19847, 2011.

[13] G. Malakasioti, E. Alexopoulos, C. Befani et al., “Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA,” *Sleep and Breathing*, vol. 16, no. 3, pp. 703–708, 2012.

[14] M. D. DeBoer, J. P. Mendoza, L. Liu, G. Ford, P. L. Yu, and B. M. Gaston, “Increased systemic inflammation overnight correlates with insulin resistance among children evaluated for obstructive sleep apnea,” *Sleep and Breathing*, vol. 16, no. 2, pp. 349–354, 2012.

[15] H.-L. Tan, D. Gozal, Y. Wang et al., “Alterations in circulating T-cell lymphocyte populations in children with obstructive sleep apnea,” *Sleep*, vol. 36, no. 6, pp. 913–922, 2013.

[16] J. Kim, D. Gozal, R. Bhattacharjee, and L. Kheirandish-Gozal, “TREM-1 and pentraxin-3 plasma levels and their association with obstructive sleep apnea, obesity, and endothelial function in children,” *Sleep*, vol. 36, no. 6, pp. 923–931, 2013.

[17] A. G. Kaditis, E. I. Alexopoulos, E. Kalampouka et al., “Morning levels of C-reactive protein in children with obstructive sleep-disordered breathing,” *American Journal of Respiratory and Critical Care Medicine*, vol. 171, no. 3, pp. 282–286, 2005.

[18] C. S. Tam, M. Wong, R. McBain, S. Bailey, and K. A. Waters, “Inflammatory measures in children with obstructive sleep apnoea,” *Journal of Paediatrics and Child Health*, vol. 42, no. 5, pp. 277–282, 2006.

[19] R. Tauman, L. M. O’Brien, and D. Gozal, “Hypoxemia and obesity modulate plasma C-reactive protein and interleukin-6 levels in sleep-disordered breathing,” *Sleep and Breathing*, vol. 11, no. 2, pp. 77–84, 2007.

[20] D. Gozal, L. D. Serpero, L. Kheirandish-Gozal, O. S. Capdevila, A. Khalyfa, and R. Tauman, “Sleep measures and morning plasma TNF-α levels in children with sleep-disordered breathing,” *Sleep*, vol. 33, no. 3, pp. 319–325, 2010.

[21] A. G. Kaditis, E. I. Alexopoulos, A. Karathanasi et al., “Adiposity and low-grade systemic inflammation modulation matrix metalloproteinase-9 levels in Greek children with sleep apnea,” *Pediatric Pulmonology*, vol. 45, no. 7, pp. 693–699, 2010.

[22] D. Gozal, L. Kheirandish-Gozal, R. Bhattacharjee, and J. Kim, “C-reactive protein and obstructive sleep apnea syndrome in children,” *Frontiers in Bioscience*, vol. 4, no. 4, pp. 2410–2422, 2012.

[23] A. G. Kaditis, D. Gozal, A. Khalyfa et al., “Variants in C-reactive protein and IL-6 genes and susceptibility to obstructive sleep apnea in children: a candidate-gene association study in European American and Southeast European populations,” *Sleep Medicine*, vol. 15, no. 2, pp. 228–235, 2014.

[24] D. Gozal, L. D. Serpero, O. S. Capdevila, and L. Kheirandish-Gozal, “Systemic inflammation in non-obese children with obstructive sleep apnea,” *Sleep Medicine*, vol. 9, no. 3, pp. 254–259, 2008.

[25] R. M. Lauer, J. Lee, and W. R. Clarke, “Factors affecting the relationship between childhood and adult cholesterol levels: the muscatine study,” *Pediatrics*, vol. 82, no. 3, pp. 309–318, 1988.

[26] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” *Science*, vol. 259, no. 5091, pp. 87–91, 1993.

[27] O. Pinhas-Hamiel, L. M. Dolan, S. R. Daniels, D. Standiford, P. R. Khoury, and P. Zeitler, “Increased incidence of non-insulin-dependent diabetes mellitus among adolescents,” *The Journal of Pediatrics*, vol. 128, no. 5, pp. 608–615, 1996.

[28] G. S. Berenson, S. R. Srinivasan, W. Bao, W. P. Newman III, R. E. Tracy, and W. A. Wattigney, “Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults,” *The New England Journal of Medicine*, vol. 338, no. 23, pp. 1650–1656, 1998.

[29] D. S. Freedman, Z. Mei, S. R. Srinivasan, G. S. Berenson, and W. H. Dietz, “Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study,” *The Journal of Pediatrics*, vol. 150, no. 1, pp. 12–17.e2, 2007.

[30] A. G. Kaditis, E. I. Alexopoulos, F. Hatzi et al., “Adiposity in relation to age as predictor of severity of sleep apnea in children with snoring,” *Sleep and Breathing*, vol. 12, no. 1, pp. 25–31, 2008.

[31] R. Bhattacharjee, J. Kim, L. Kheirandish-Gozal, and D. Gozal, “Obesity and obstructive sleep apnea syndrome in children: a tale of inflammatory cascades,” *Pediatric Pulmonology*, vol. 46, no. 4, pp. 313–323, 2011.

[32] D. Gozal and L. Kheirandish-Gozal, “Childhood obesity and sleep: relatives, partners, or both?—A critical perspective on the evidence,” *Annals of the New York Academy of Sciences*, vol. 1264, no. 1, pp. 135–141, 2012.

[33] J. Kim, R. Bhattacharjee, L. Kheirandish-Gozal et al., “Insulin sensitivity, serum lipids, and systemic inflammatory markers in school-aged obese and nonobese children,” *International Journal of Pediatrics*, vol. 2010, Article ID 846098, 6 pages, 2010.

[34] M. L. Alonso-Álvarez, J. A. Cordero-Guevara, J. Terán-Santos et al., “Obstructive sleep apnea in obese community dwelling children: the NANOS Study,” *Sleep*, vol. 37, no. 5, pp. 943–949, 2014.

[35] M. T. Vila, A. M. Torres, and B. B. Soto, “Spanish version of the Pediatric Sleep Questionnaire (PSQ). A useful instrument in investigation of sleep disturbances in childhood. Reliability analysis,” *Anales de Pediatría*, vol. 66, no. 2, pp. 121–128, 2007.

[36] R. B. Berry, R. Budhiraja, D. J. Gottlieb et al., “Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events,” *Journal of Clinical Sleep Medicine*, vol. 8, no. 5, pp. 597–619, 2012.

[37] M. L. Alonso-Álvarez, T. Canet, M. Cubell-Alarco et al., “Documento de consenso del síndrome de apneas-hipopneas durante el sueño en niños (versión completa),” *Archivos de Bronconeumología*, vol. 47, supplement 5, pp. 2–18, 2011.

[38] B. Sobradillo, B. A. A. U. Aresti, C. Bilbao, C. Fernández-Ramos, A. Lizarraga et al., “Curvas y tablas de crecimiento (estudio longitudinal y transversal),” in *Patrones de Crecimiento y Desarrollo en España: Atlas de Gráficas y Tablas*, F. F. Orbegozo, Ed., pp. 145–168, Ergon, Madrid, Spain, 2004.
[39] P. Sartipy and D. J. Loskutoff, “Monocyte chemoattractant protein 1 in obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 12, pp. 7265–7270, 2003.

[40] I. Dahlman, M. Kaaman, T. Olsson et al., “A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 10, pp. 5834–5840, 2005.

[41] A. E. Malavazos, E. Cereda, L. Morricone, C. Coman, M. M. Corsi, and B. Ambrosi, “Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity,” European Journal of Endocrinology, vol. 153, no. 6, pp. 871–877, 2005.

[42] A. Ito, T. Suganami, Y. Miyamoto et al., “Role of MAPK phosphatase 1 in the induction of monocyte chemoattractant protein 1,” Journal of Biological Chemistry, vol. 282, no. 35, pp. 25445–25452, 2007.

[43] G. Daniele, R. G. Mendoza, D. Winnier et al., “The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus,” Acta Diabetologica, vol. 51, no. 1, pp. 123–131, 2014.

[44] Y. Ma, A. Yabluchanskiy, M. E. Hall, and M. L. Lindsey, “Using plasma matrix metalloproteinase-9 and monocyte chemotactant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis,” Atherosclerosis, vol. 232, no. 1, pp. 231–233, 2014.

[45] A. D. Schecter, B. J. Rollins, Y. J. Zhang et al., “Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells,” The Journal of Biological Chemistry, vol. 272, no. 45, pp. 28568–28573, 1997.

[46] G. Cai, S. A. Cole, N. F. Butte et al., “A genetic contribution to circulating cytokines and obesity in children,” Cytokine, vol. 44, no. 2, pp. 242–247, 2008.

[47] W. L. Breslin, C. A. Johnston, K. Strohacker et al., “Obese Mexican American children have elevated MCP-1, TNF-α, monocyte concentration, and dyslipidemia,” Pediatrics, vol. 129, no. 5, pp. e1180–e1186, 2012.

[48] E. Ohga, T. Tomita, H. Wada, H. Yamamoto, T. Nagase, and Y. Ouchi, “Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1,” Journal of Applied Physiology, vol. 94, no. 1, pp. 179–184, 2003.

[49] J. Kim, C. H. Lee, C. S. Park, B. G. Kim, S. W. Kim, and J. H. Cho, “Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome,” Archives of Otolaryngology—Head & Neck Surgery, vol. 136, no. 9, pp. 896–899, 2010.

[50] M. Hayashi, K. Fujimoto, K. Urushibata, A. Takamizawa, O. Kinoshita, and K. Kubo, “Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome,” Respiration, vol. 81, no. 1, pp. 24–31, 2006.

[51] D. E. Vaughan, “PAI-1 and atherothrombosis,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1879–1883, 2005.

[52] M. M. Smits, P. Woudstra, K. M. Utschneider et al., “Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis,” Annals of Epidemiology, vol. 23, no. 7, pp. 415–421, 2013.

[53] A. A. Adly, N. S. Elbarbary, E. A. Ismail, and S. R. Hassan, “Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents With Type 1 Diabetes Mellitus: relation to diabetic microvascular complications and carotid intima media thickness,” Journal of Diabetes and Its Complications, vol. 28, no. 3, pp. 340–347, 2014.

[54] K. Bagai et al., “Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea,” Sleep, vol. 37, no. 2, pp. 359–367, 2014.

[55] R. von Kanel, L. Natarajan, S. Ancoli-Israel, P. J. Mills, J. S. Lorenzo, and J. E. Dimsdale, “Day/night rhythm of hemostatic factors in obstructive sleep apnea,” Sleep, vol. 33, no. 3, pp. 371–377, 2010.

[56] H.-L. Tan, D. Gozal, A. Samiei et al., “T regulatory lymphocytes and endothelial function in pediatric obstructive sleep apnea,” PLoS ONE, vol. 8, no. 7, Article ID e69710, 2013.

[57] L. Kheirandish-Gozal, O. Khalyfa, D. Gozal, R. Bhattacharjee, and Y. Wang, “Endothelial dysfunction in children with obstructive sleep apnea is associated with epigenetic changes in the eNOS gene,” Chest, vol. 143, no. 4, pp. 971–977, 2013.

[58] L. Kheirandish-Gozal, T. Etzioni, R. Bhattacharjee et al., “Obstructive sleep apnea in children is associated with severity-dependent deterioration in overnight endothelial function,” Sleep Medicine, vol. 14, no. 6, pp. 526–531, 2013.

[59] G. Luc, J. M. Bard, I. Juhan-Vague et al., “C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1255–1261, 2003.

[60] R. Tauman, A. Ivanenko, L. M. O’Brien, and D. Gozal, “Plasma C-reactive protein levels among children with sleep-disordered breathing,” Pediatrics, vol. 113, no. 6, pp. e564–e569, 2004.

[61] M. M. Ciccone, P. Scicchitano, A. Zito et al., “Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in obstructive sleep apnea,” Molecules, vol. 19, no. 2, pp. 1651–1662, 2014.

[62] R. Nadeem et al., “Serum inflammatory markers in obstructive sleep apnea: a meta-analysis,” Journal of Clinical Sleep Medicine, vol. 9, no. 10, pp. 1003–1012, 2013.

[63] R. Tauman, L. M. O’Brien, A. Ivanenko, and D. Gozal, “Obesity rather than severity of sleep-disordered breathing as the major determinant of insulin resistance and altered lipidemia in snoring children,” Pediatrics, vol. 116, no. 1, pp. e66–e73, 2005.

[64] R. Tauman, L. D. Serpero, O. S. Capdevila et al., “Adipokines in children with sleep disordered breathing,” Sleep, vol. 30, no. 4, pp. 443–449, 2007.

[65] L. Kheirandish-Gozal, R. Bhattacharjee, H. P. Bandla, and D. Gozal, “Anti-inflammatory therapy outcomes for mild OSA in children,” Chest, 2014.

[66] K. L. Knutson and E. Van Cauter, “Associations between sleep and obesity in children’s sleep duration on food intake, weight, and leptin,” Pediatrics, vol. 132, no. 6, pp. e1473–e1480, 2013.

[67] C. N. Hart, M. A. Carskadon, R. V. Considine et al., “Changes in children's sleep duration on food intake, weight, and leptin,” Pediatrics, vol. 132, no. 6, pp. e1473–e1480, 2013.

[68] B. Mokhlesi, “Obesity hypoventilation syndrome: a state-of-the-art review,” Respiratory Care, vol. 55, no. 10, pp. 1347–1365, 2010.

[69] S. Nowbar, K. M. Burkart, R. Gonzales et al., “Obesity-Associated hypventilation in hospitalized patients: prevalence, effects, and outcome,” The American Journal of Medicine, vol. 116, no. 1, pp. 1–7, 2004.
[70] A. BaHammam, S. Syed, and A. Al-Mughairy, “Sleep-related breathing disorders in obese patients presenting with acute respiratory failure,” *Respiratory Medicine*, vol. 99, no. 6, pp. 718–725, 2005.

[71] J.-L. Pépin, J.-C. Borel, and J.-P. Janssens, “Obesity hypventilation syndrome: an underdiagnosed and undertreated condition,” *American Journal of Respiratory and Critical Care Medicine*, vol. 186, no. 12, pp. 1205–1207, 2012.

[72] A. Alzaabi, S. Fizal, R. Moilothkandy, B. Mahboub, and N. Nagelkerke, “Obesity hypoventilation syndrome in obstructive sleep apnea patients in the United Arab Emirates: a retrospective cross-sectional study,” *JRSM Short Reports*, vol. 4, no. 12, 2013.

[73] S. Redline, P. V. Tishler, M. Schluchter, J. Aylor, K. Clark, and G. Graham, “Risk factors for sleep-disordered breathing in children: associations with obesity, race, and respiratory problems,” *American Journal of Respiratory and Critical Care Medicine*, vol. 159, no. 5, part 1, pp. 1527–1532, 1999.

[74] M.-A. Carno, J. Modrak, R. Short, E. R. Ellis, and H. V. Connolly, “Sleep associated gas exchange abnormalities in children and adolescents with habitual snoring,” *Pediatric Pulmonology*, vol. 44, no. 4, pp. 364–372, 2009.